M&T Bank Corp increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 9.4% during the 4th ...

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was ...

StockNews.com lowered shares of United Therapeutics (NASDAQ:UTHR – Free Report) from a strong-buy rating to a buy rating in a ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile ...

In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on United Therapeutics (UTHR – Research Report), with a ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Despite risks from patent expirations and legal challenges, UTHR's diversified portfolio and strong financials position it well for sustained growth. Any investor who wants to invest money in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reports Q4 revenue $735.9M, consensus $734.74M. “I want to congratulate every Unitherian for their relentless dedication, which has allowed us ...

UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $6.19 per share, missing estimates of $6. ...